A clinical-stage AbbVie focused on next-generation inflammation treatments, with an added interest in advanced CBD therapeutics.

Imagine GW Pharmaceuticals (maker of Epidiolex) if it also developed novel drugs for chronic inflammation.

• MYMD-1: A drug platform designed to regulate the immune system to treat diseases and disorders marked by acute or chronic inflammation.
• Supera-CBD: A novel synthetic derivative of cannabidiol (CBD) being developed to treat chronic pain, addiction, and epilepsy.

TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.), which trades under the symbol QCLS, is a clinical-stage pharmaceutical company. This means it is currently focused on the research, development, and clinical trials of its drug platforms, MYMD-1 and Supera-CBD, rather than on the commercial sale of approved products.

As a clinical-stage company, TNF Pharmaceuticals, Inc. does not currently have major commercial customers (either other companies or individual consumers) from the sale of its therapeutic products. Its primary activities involve advancing its drug candidates through various phases of clinical development and seeking regulatory approvals.

Joshua Silverman, Executive Chairman and Principal Executive Officer

Joshua Silverman serves as the Executive Chairman and Principal Executive Officer of Q/C Technologies, Inc.. He previously held the position of Chairman of the Board for MyMD Pharmaceuticals, Inc., the company's predecessor, having joined its board in September 2018. Silverman is an experienced investment banker and management consultant. He co-founded and served as co-chief investment officer of Iroquois Capital Management, LLC, an investment advisory firm, from 2003 to 2016. Prior to that, he was co-chief investment officer of Vertical Ventures, LLC, a merchant bank, from 2000 to 2003. He has served on the boards of directors for several public companies, including AYRO, Inc., Protagenic Therapeutics, Neurotrope, Inc., Petros Pharmaceuticals, Inc., and Synaptogenix, Inc.. Earlier in his career, Silverman was a Director at Joele Frank, a firm specializing in mergers and acquisitions, and also served as Assistant Press Secretary to the President of the United States. He is currently also the interim Chief Executive Officer, President, and Director of PharmaCyte Biotech.

Ian Rhodes, Interim Chief Financial Officer

Ian Rhodes is the Interim Chief Financial Officer of Q/C Technologies, Inc.. He was initially appointed as Interim Chief Financial Officer for MyMD Pharmaceuticals, Inc. on February 1, 2021, and has continued in this role through the company's transitions. Rhodes began his career at PricewaterhouseCoopers, where he worked for 15 years. His prior experience includes serving as Interim CFO for Roadway Moving and Storage from March 2020 to December 2020, and for Greyston Bakery and Foundation from November 2018 to July 2019. He also held the positions of President, CEO, and Director of GlyEco, Inc. from December 2016 to September 2018, having previously served as its CFO from February 2016 to December 2016. From May 2014 to January 2016, he was the CFO of Calmare Therapeutics. Rhodes is a licensed CPA in New York and holds a Bachelor of Science degree in Business Administration with a concentration in Accounting from Seton Hall University.

Mitchell Glass, M.D., Chief Medical Officer

Mitchell Glass, M.D., serves as the Chief Medical Officer of Q/C Technologies, Inc.. He was appointed President and Chief Medical Officer of MyMD Pharmaceuticals, Inc., the company's predecessor, in June 2024, and was also a member of its board of directors. Dr. Glass brings over 35 years of experience in the life sciences sector, with a track record of multiple drug approvals including Accolate®, Avandia®, and Coreg®. His extensive background includes guiding companies through regulatory processes, with 5 New Drug Applications (NDAs), 7 pre-NDA meetings, 12 End of Phase 2 (EOP2) meetings with the FDA, and more than 80 Investigational New Drug (IND) applications. Dr. Glass is board-certified in internal medicine, pulmonary, and critical care medicine, with a specialized focus on inflammatory diseases and immunopathology. His career spans various executive roles at major pharmaceutical companies, as well as founding, leading, and funding start-up and early-stage biopharma ventures. He is a founder and principal of Medpro Investors, a New York-based venture capital firm focused on the healthcare sector. Prior to his tenure at the Science Center, Dr. Glass held positions as Chief Medical Officer for AtheroGenics, Inc., and Vice President and Director of Cardiopulmonary Clinical Research, Development, and Medical Affairs at SmithKline Beecham.

1. Market Volatility and Technological Uncertainty in Quantum-Class Computing and Blockchain: Q/C Technologies has explicitly shifted its strategic focus to developing quantum-class photonic computing for cryptocurrency and blockchain applications. This market is highly speculative, characterized by extreme volatility in asset prices, rapid technological changes, intense competition, and an uncertain regulatory landscape. The successful commercialization and widespread adoption of their technology in this nascent and rapidly evolving field are subject to significant uncertainty.
2. High Failure Rate and Regulatory Hurdles in Clinical-Stage Pharmaceutical Development: Despite the strategic pivot, Q/C Technologies (formerly TNF Pharmaceuticals) continues to possess a pipeline of clinical-stage drug candidates, including MYMD-1 and Supera-CBD, as outlined in the background. Pharmaceutical development, particularly at the clinical stage, inherently carries a very high risk of failure during trials. Even if trials are successful, drugs face stringent, lengthy, and costly regulatory approval processes, with no guarantee of market authorization.
3. Execution Risk of a Dual Business Model and Strategic Pivot: The company's recent and significant strategic pivot from a purely pharmaceutical focus to one emphasizing advanced computing for blockchain, potentially while still advancing pharmaceutical assets, presents substantial execution risks. Effectively managing two distinct and complex business models, requiring disparate expertise and significant resource allocation, could strain the company's financial, operational, and managerial capabilities, potentially hindering the success of both ventures.